MediciNova Announces Completion of Enrollment in a Phase II Multiple Sclerosis Trial With MN-166

Feb 06, 2006, 00:00 ET from MediciNova, Inc.

    SAN DIEGO, Feb. 6 /PRNewswire/ -- MediciNova, Inc., a specialty
 pharmaceutical company that is publicly traded on the Hercules Market of the
 Osaka Securities Exchange (Code Number: 4875), today announced completion of
 enrollment of 297 patients with relapsing multiple sclerosis (MS) in its
 Phase II clinical trial of MN-166.
     MN-166 is a novel, orally administered compound being evaluated for the
 treatment of MS.  In July 2005, MediciNova initiated a randomized,
 double-blind, placebo-controlled multi-center Phase II clinical trial of
 MN-166 in MS patients in Eastern Europe.  Two hundred and ninety-seven (297)
 patients have been randomized to receive placebo or one of two doses of MN-166
 in this trial.  Efficacy data is expected after one year of treatment (in this
 two year trial) in 1Q07.
     MN-166 inhibits leukotriene activity, phosphodiesterases and nitric oxide
 synthase, all inflammatory mechanisms known to be involved in MS.  Recently,
 MN-166 was found to have beneficial effects in several pilot clinical trials
 conducted in MS patients in Japan.  These findings led to the issuance of a
 new U.S. method of use patent for MN-166 in 2002.
     "MN-166 may be an effective new approach to treating MS with the added
 advantage of oral dosing.  Rapid completion of enrollment in this relatively
 large trial demonstrates our commitment to advancing our clinical programs
 efficiently though the Phase II proof-of-concept stage and beyond," said
 Yuichi Iwaki, M.D., Ph.D., Executive Chairman and Acting CEO of MediciNova,
     MediciNova acquired the rights to MN-166 from Kyorin Pharmaceutical Co.
 Ltd. for global markets excluding Japan, China, Taiwan and South Korea.  For
 the past 16 years, MN-166 has been marketed in Japan and South Korea as
 Ketas(R) for the treatment of asthma and cerebrovascular disorders.  Data from
 the existing clinical trial and post-marketing surveillance databases, which
 includes treatment of an estimated 3.2 million patients with these disorders,
 indicate that Ketas(R) is well tolerated.
     About MediciNova
     MediciNova, Inc. is a publicly traded specialty pharmaceutical company
 focused on accelerating the global development and commercialization of
 innovative pharmaceutical products.  MediciNova's pipeline, which includes
 several compounds in clinical testing, targets a variety of prevalent medical
 conditions, including cancer, asthma, Generalized Anxiety Disorder, multiple
 sclerosis, interstitial cystitis, preterm labor and urinary incontinence.  For
 more information on MediciNova, Inc., please visit
     This press release may contain "forward looking statements" within the
 meaning of the Private Securities Litigation Reform Act of 1995.  These
 statements include statements regarding clinical trials supporting efficacy of
 one of our product candidates as well as the potential novelty of that
 candidate as a treatment for disease.  These statements are based on certain
 assumptions made by the Company's management that are believed to be
 reasonable at the time.  Such statements are subject to a number of risks and
 uncertainties, many of which are beyond the control of the Company, including
 the results of clinical studies and other risks and uncertainties, including
 those described in the Company's filings with the Securities and Exchange
 Commission.  These assumptions, risks and uncertainties could cause the
 Company's actual results to differ materially from those implied or expressed
 by the forward-looking statements.

SOURCE MediciNova, Inc.